SF3B1 and myelodysplastic syndrome: One study, which retrospectively evaluated luspatercept in MDS-RS patients in routine clinical practice, found limited value in securing durable anemia responses [59], while a single institution case series demonstrated potential clinical benefit in patients with LR-MDS with RS and SF3B1 mutation [60].